• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Augmedix and SADA Forge Partnership to Scale Ambient Documentation and Structured Data Products to Health Systems Nationwide

    4/4/24 7:00:00 AM ET
    $AUGX
    Business Services
    Consumer Discretionary
    Get the next $AUGX alert in real time by email

    SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today announced its go-to-market partnership with SADA, an Insight company, a leading cloud business and technology consultancy. The collaboration is focused on leveraging the companies' combined technology expertise and expanding their reach to provide greater product and service value to health systems seeking high-quality ambient documentation and structured data products.

    "We are thrilled to join forces with SADA, to partner with an organization that has a nationwide reach to health systems, and also to leverage their prowess in frontier cloud infrastructure technology, machine learning, integrations, and implementations," said Ian Shakil, founder, director, and chief strategy officer of Augmedix. "Together, we can accelerate efforts to bring ambient medical documentation and data solutions to benefit more patients and clinicians."

    SADA provides cloud, data, artificial intelligence, cybersecurity, and intelligent edge solutions and services. It is also a service partner for Google Cloud with 10 specializations, including security, infrastructure, cloud migration, data analytics, application development, location-based services, and machine learning. SADA offers unique expertise in frontier Google Cloud Platform (GCP) integrations, focusing on generative AI models, especially MedLM, a family of models fine-tuned for healthcare industry use cases.

    "SADA is proud to have provided Augmedix with technical services for many years," said Michael Ames, managing director of Healthcare and Life Sciences Professional Services. "Now, as part of Insight, we are excited to embark on a new phase of partnership, bringing together our expertise in data and analytics, Insight's vast reach in the healthcare industry, and Augmedix's cutting-edge technology to accelerate scalable enterprise adoption for Augmedix. Our combined entities' reach and capabilities will empower us to advance Augmedix's products beyond core charting. This partnership represents our commitment to pushing the boundaries of what's possible in healthcare and cloud technology."

    As a Google Cloud Premier Partner across several product and engagement models, SADA has deep engineering capabilities across the entire Google Cloud stack and specializes in Google Cloud priority workloads. The go-to-market partnership enables SADA to closely work on reference architecture with Google Cloud and Augmedix, further accelerating Augmedix's positioning as an innovation partner.

    "Augmedix's partnership with SADA will help bring ambient documentation to more healthcare organizations around the country," said Amy Waldron, global director of Healthcare Strategy & Solutions, Google Cloud. "Importantly, this work will help improve how medical data is captured, enhancing efficiency, and ultimately improving patient care. This collaboration underscores our commitment to empowering organizations like Augmedix and SADA to drive meaningful change in the healthcare industry."

    About Augmedix

    Augmedix (NASDAQ:AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and trust.

    The platform transforms natural conversations into organized medical notes, structured data, and point-of-care notifications that enhance efficiency and clinical decision support.

    Incorporating data from millions of interactions across all care settings, Augmedix collaborates with hospitals and health systems to improve clinical, operational, and financial outcomes.

    Augmedix is headquartered in San Francisco, CA, with offices around the world. To learn more, visit www.augmedix.com.

    About SADA, an Insight Company

    SADA, An Insight company, is a market leader in professional services and an award-winning solutions provider of Google Cloud. Since 2000, SADA has been committed to helping customers in healthcare, media, entertainment, retail, manufacturing, and the public sector solve their most complex challenges so they can focus on achieving their boldest ambitions. With offices in North America, India, and Armenia providing sales and customer support teams, SADA is positioned to meet customers where they are in their digital transformation journey. SADA is a 6x Google Cloud Partner of the Year award winner with 10 Google Cloud Specializations and has been recognized as a Niche Player in the 2023 Gartner® Magic Quadrant™ for Public Cloud IT Transformation Services. SADA has been named to Inc. Magazine's Best Workplaces four years in a row. Learn more at www.sada.com.

    Contact Information

    Investors:

    Matt Chesler, CFA

    FNK IR

    646-809-2183

    [email protected]

    [email protected]

    Media:

    Kaila Grafeman

    Augmedix

    [email protected]

    Forward-Looking Statements

    This press release contains "forward-looking statements" that involve a number of risks and uncertainties. Words such as "believes," "may," "will," "estimates," "potential," "continues," "anticipates," "intends," "expects," "could," "would," "projects," "plans," "targets," "excited," "optimistic," and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the partnership enabling Augmedix to accelerate scaling efforts for digital health solutions and integrations that work seamlessly at the point of care; accelerating our efforts to bring ambient medical documentation and data solutions to benefit more patients and clinicians; furthering Augmedix's positioning as an innovation partner; Augmedix's partnership with SADA and Google Cloud representing a pivotal moment in healthcare technology; and being poised to revolutionize how medical data is captured, enhancing efficiency and improving patient care. Actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in our most recent Form 10-K filed with the U.S. Securities and Exchange Commission on March 26, 2024, as well as other documents that may be filed by us from time to time with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.



    Primary Logo

    Get the next $AUGX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AUGX

    DatePrice TargetRatingAnalyst
    7/22/2024Buy → Hold
    Lake Street
    7/22/2024$3.00 → $2.35Buy → Neutral
    B. Riley Securities
    5/14/2024$5.00Buy → Hold
    Maxim Group
    5/14/2024$5.00 → $1.50Outperform → In-line
    Evercore ISI
    4/3/2024$5.50Buy
    B. Riley Securities
    12/15/2023$6.00In-line
    Evercore ISI
    3/7/2022$6.00Buy
    Lake Street
    1/21/2022$6.00Buy
    Maxim Group
    More analyst ratings

    $AUGX
    SEC Filings

    View All

    SEC Form 15-12G filed by Augmedix Inc.

    15-12G - Augmedix, Inc. (0001769804) (Filer)

    10/15/24 9:32:28 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    SEC Form EFFECT filed by Augmedix Inc.

    EFFECT - Augmedix, Inc. (0001769804) (Filer)

    10/4/24 12:15:04 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    SEC Form EFFECT filed by Augmedix Inc.

    EFFECT - Augmedix, Inc. (0001769804) (Filer)

    10/4/24 12:15:02 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    $AUGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Redmile Group, Llc returned $75,402,504 worth of shares to the company (32,086,172 units at $2.35) (SEC Form 4)

    4 - Augmedix, Inc. (0001769804) (Issuer)

    10/4/24 5:01:03 PM ET
    $AUGX
    Business Services
    Consumer Discretionary

    SEC Form 4 filed by Director Faulkner Robert C.

    4 - Augmedix, Inc. (0001769804) (Issuer)

    10/4/24 5:00:14 PM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Director Febbo William J returned $382,070 worth of shares to the company (162,583 units at $2.35), closing all direct ownership in the company (SEC Form 4)

    4 - Augmedix, Inc. (0001769804) (Issuer)

    10/4/24 1:17:00 PM ET
    $AUGX
    Business Services
    Consumer Discretionary

    $AUGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Augmedix downgraded by Lake Street

    Lake Street downgraded Augmedix from Buy to Hold

    7/22/24 8:25:03 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Augmedix downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded Augmedix from Buy to Neutral and set a new price target of $2.35 from $3.00 previously

    7/22/24 8:02:58 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Augmedix downgraded by Maxim Group with a new price target

    Maxim Group downgraded Augmedix from Buy to Hold and set a new price target of $5.00

    5/14/24 8:17:17 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    $AUGX
    Financials

    Live finance-specific insights

    View All

    Commure Completes Merger with Augmedix

    SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market. "I started Augmedix to relieve clinic

    10/2/24 8:23:42 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Augmedix to Announce Second Quarter 2024 Financial Results on August 12, 2024

    SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today it anticipates releasing second quarter 2024 results after the market closes on Monday, August 12, 2024. On July 19, 2024, Augmedix announced that it entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems. Due to this pending acquisition, management is not hosting a quarterly conference call. About Augmedix Augmedix (NASDAQ:AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and

    8/6/24 7:00:00 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Augmedix Delivers 40% Revenue Growth for First Quarter of 2024

    SAN FRANCISCO, May 13, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended March 31, 2024. "Augmedix delivered in-line first quarter performance, with 40% revenue growth, 143% net revenue retention and 47.1% gross margins," commented Manny Krakaris, Augmedix CEO. "We are confident about our positioning within the medical documentation market, and expect to report continued growth throughout the rest of the year. It is now clear, however, that health systems are proceeding methodically while they develop a better understanding of the capabilities of AI products." "We a

    5/13/24 4:03:00 PM ET
    $AUGX
    Business Services
    Consumer Discretionary

    $AUGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Augmedix Inc.

    SC 13D/A - Augmedix, Inc. (0001769804) (Subject)

    10/4/24 5:00:14 PM ET
    $AUGX
    Business Services
    Consumer Discretionary

    SEC Form SC 13G filed by Augmedix Inc.

    SC 13G - Augmedix, Inc. (0001769804) (Subject)

    7/29/24 5:23:20 PM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Augmedix Inc.

    SC 13D/A - Augmedix, Inc. (0001769804) (Subject)

    7/19/24 7:45:47 PM ET
    $AUGX
    Business Services
    Consumer Discretionary

    $AUGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Commure Completes Merger with Augmedix

    SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure. The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix's special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix's stock has ceased trading and will be delisted from the Nasdaq Stock Market. "I started Augmedix to relieve clinic

    10/2/24 8:23:42 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024

    SAN FRANCISCO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today reported financial results for the three months ended June 30, 2024. "We believe we are approaching the proposed combination with Commure, Inc. from a position of strength, with consistent double-digit revenue growth and improving gross margins," commented Manny Krakaris, Augmedix CEO. "Together, we believe we will be well-positioned to continue to streamline the medical documentation ecosystem with a growing base of health system customers, solid partners, and proven solutions. As part of Commure, we expect to scale our ambient documentation solu

    8/12/24 4:01:00 PM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Augmedix to Announce Second Quarter 2024 Financial Results on August 12, 2024

    SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, announced today it anticipates releasing second quarter 2024 results after the market closes on Monday, August 12, 2024. On July 19, 2024, Augmedix announced that it entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems. Due to this pending acquisition, management is not hosting a quarterly conference call. About Augmedix Augmedix (NASDAQ:AUGX) empowers clinicians to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and

    8/6/24 7:00:00 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    $AUGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Ginocchio Paul bought $48,500 worth of shares (10,000 units at $4.85), increasing direct ownership by 8% to 128,000 units (SEC Form 4)

    4 - Augmedix, Inc. (0001769804) (Issuer)

    11/27/23 7:00:06 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Redmile Group, Llc bought $6,000,000 worth of shares (1,500,000 units at $4.00) (SEC Form 4)

    4 - Augmedix, Inc. (0001769804) (Issuer)

    11/22/23 4:15:24 PM ET
    $AUGX
    Business Services
    Consumer Discretionary

    $AUGX
    Leadership Updates

    Live Leadership Updates

    View All

    Augmedix to Join Forces with Commure

    SAN FRANCISCO, July 19, 2024 (GLOBE NEWSWIRE) -- Augmedix, Inc. (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today announced that it has entered into a definitive agreement to be acquired by Commure, Inc., a leading provider of technology to healthcare systems, in an all-cash transaction that values Augmedix at approximately $139 million in equity value. Under the terms of the agreement, Augmedix stockholders will receive $2.35 per share in cash upon completion of the proposed transaction, and Augmedix will become a wholly-owned subsidiary of Commure. The purchase price represents a premium of approximately 169% over the volume weighted average price

    7/19/24 7:00:00 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Augmedix Appoints Alex Stinard, M.D., as Chief Clinical AI Officer

    SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient artificial intelligence (AI) medical documentation and data solutions, today announced that Alex Stinard, M.D., has been named Chief Clinical AI Officer of the company. Dr. Stinard brings over two decades of extensive experience as an emergency medicine clinician. He has a background in data science with a specialization in large language models, computer vision, and natural language processing. This mix of experience makes Dr. Stinard uniquely qualified for this new position. "Welcoming Dr. Stinard to join Augmedix in this new role is an exciting step forward in implementing advanced AI technolog

    5/29/24 7:00:00 AM ET
    $AUGX
    Business Services
    Consumer Discretionary

    Augmedix and SADA Forge Partnership to Scale Ambient Documentation and Structured Data Products to Health Systems Nationwide

    SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Augmedix (NASDAQ:AUGX), a leader in ambient AI medical documentation and data solutions, today announced its go-to-market partnership with SADA, an Insight company, a leading cloud business and technology consultancy. The collaboration is focused on leveraging the companies' combined technology expertise and expanding their reach to provide greater product and service value to health systems seeking high-quality ambient documentation and structured data products. "We are thrilled to join forces with SADA, to partner with an organization that has a nationwide reach to health systems, and also to leverage their prowess in frontier cloud infr

    4/4/24 7:00:00 AM ET
    $AUGX
    Business Services
    Consumer Discretionary